Status:
COMPLETED
Immune Responses With Reduxium
Lead Sponsor:
Ogevity Therapeutics, Inc.
Collaborating Sponsors:
National University of Singapore
Conditions:
Immune Tolerance
Viral Infection
Eligibility:
All Genders
21-50 years
Phase:
NA
Brief Summary
Reduxium is a dietary supplement that provides immune support. This natural compound is orally-ingested in the form of droplets in water to boost the immune system and control inflammation. There is n...
Detailed Description
With the global population increasingly exposed to pandemic crises, permanent and expedient solutions are needed at an affordable cost. Vaccination is less than ideal as the virus is prone to a mutati...
Eligibility Criteria
Inclusion
- Subjects of 21 - 50 years of age
- Normal blood pressure (BP \<140/90 nnHg)
- Normal fasting glucose (\<6mmol/L)
- Subjects must stop all supplement for 1 month prior to enrolment
Exclusion
- Subjects with known history of lungs or cardiovascular disease
- History of previous pancreatitis
- Past or current history of malignancy
- Subjects with type 2 diabetes
- Past or current history of peptic ulcer disease
- Current pregnancy or breastfeeding
Key Trial Info
Start Date :
October 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 27 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04525456
Start Date
October 7 2020
End Date
January 27 2021
Last Update
May 27 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
National University of Singapore - The N.1 Institute for Health
Singapore, Singapore, 117456
2
National University of Singapore - Yong Loo Lin School of Medicine
Singapore, Singapore, 117597
3
National University Hospital
Singapore, Singapore, 119074